SEC Form 4 · accession 0001104659-17-040454
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth J Zuerblis
Director
Period of report
Jun 19, 2017
Accepted (ET)
Jun 20, 2017 · 5:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jun 19, 2017 | A | 10,000 | $0.00 | A | 31,963 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F3 | $8.20 | Jun 19, 2017 | A | 24,000 | A | Jun 19, 2018 | Jun 19, 2027 | Common Stock | 24,000 | 24,000 | D |
Explanation of responses
- F1The restricted shares will vest according to the following schedule: 3,334 shares on 6/19/2018, 3,333 shares on 6/19/2019 and 3,333 shares on 6/19/2020.
- F2Of the 31,963 shares, 16,666 shares are restricted stock.
- F3The options will vest according to the following schedule: one-third on each of 6/19/2018, 6/19/2019, and 6/19/2020.